ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

TYRU Tyratech (DI)

3.00
0.00 (0.00%)
24 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Tyratech (DI) LSE:TYRU London Ordinary Share COM SHS USD0.001 (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.00 2.80 3.20 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

TyraTech, Inc. Joint Development and License Agreement (0977K)

04/07/2017 2:29pm

UK Regulatory


Tyratech (DI) (LSE:TYRU)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Tyratech (DI) Charts.

TIDMTYR TIDMTYRU

RNS Number : 0977K

TyraTech, Inc.

04 July 2017

4th July 2017

TyraTech, Inc.

("TyraTech" or the "Company")

TyraTech announces Joint Development and License Agreement between

Envance Technologies LLC and a Major Global Consumer Products Company

TyraTech Inc. (AIM: TYR, and TYRU), a life sciences company focused on nature-derived insect and parasite control products, today announces that Envance Technologies LLC (Envance) has entered a Joint Development and License Agreement (the "Agreement") with a major global consumer products company (the "Corporation) to develop and commercialize a range of pest control household products based on TyraTech's nature-derived technologies.

Envance is a joint venture between American Vanguard Corporation (NYSE: AVD) (AMVAC) which holds a 86.67% interest and TyraTech which holds 13.33%. AMVAC is also a 15.15% shareholder in TyraTech.

The Agreement sub-licenses Envance's existing rights to TyraTech's intellectual property ("IP") and knowhow with applications in the consumer household pest control sector to the Corporation. The Agreement specifically excludes personal care products, which are the sole property of TyraTech, such as the Vamousse(R) range of head lice treatments; Guardian(TM) personal insect repellants; as well as Animal Health applications.

TyraTech will benefit from this agreement in several ways. First, all parties will share technology and expertise in the development of new products for use in controlling pests in the home environment, and new intellectual property created will be jointly owned. Significantly, TyraTech will gain the right to use the new IP in its own fields (personal care and animal health).

Second, TyraTech will be entitled to a small share of the profit of Envance, derived from the royalties on the Corporation's net sales of these products. Separately, in recognition of the addition of further IP in the same household sector, Envance will pay TyraTech associated royalties and an additional upfront cash fee of $500,000 which will be used to fund normal working capital.

Third, it is envisaged that TyraTech will also be involved in the development of the new products in the first few years of the Agreement, which is being fully funded by Envance. TyraTech will receive a fee in relation to research and development services in line with the terms of its existing agreement with Envance.

All other terms of the Agreement are subject to strict confidentiality clauses.

Bruno Jactel CEO of TyraTech said: "This Agreement is an excellent endorsement of our Technology by one of the largest consumer products companies in the world. It will also enable us to use technology developed jointly into our own areas of operation. Although the agreement is not expected to be transformational in terms of profitability, it provides us with further confidence in the significant value of our IP and knowhow and the potential and value of our Animal Health and Personal Care portfolios."

This announcement is part of on-going normal course of business and not part of the strategic review. The strategic review is progressing to plan and timetable and a further update will be given in due course.

The sale of intellectual property to Envance constitutes a related party transaction for the purposes of the AIM Rules (the"Related Party Transaction"). The Independent Directors of TyraTech consider, having consulted with the Company's nominated adviser, that the terms of the Related Party Transaction are fair and reasonable insofar as the Company's shareholders are concerned.

-ends-

For further information:

 
TyraTech Inc. 
 Bruno Jactel, Chief Executive         Tel: +1 919 415 
 Officer                               4340 
 Erica H. Boisvert, Chief Financial    Tel: +1 919 415 
 Officer                               4287 
 www.tyratech.com 
 
  SPARK Advisory Partners Limited 
  (Nominated Adviser)                  Tel: +44 20 3368 
  Matt Davis / Mark Brady              3551 
 
  Allenby Capital Limited (Broker) 
  Chris Crawford                       Tel: +44 20 3328 
                                       5656 
 
Belvedere Communications (PR)        Tel: +44 20 3567 
 John West / Kim van Beeck            0510 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

AGRSSWFDLFWSEEW

(END) Dow Jones Newswires

July 04, 2017 09:29 ET (13:29 GMT)

1 Year Tyratech (DI) Chart

1 Year Tyratech (DI) Chart

1 Month Tyratech (DI) Chart

1 Month Tyratech (DI) Chart

Your Recent History

Delayed Upgrade Clock